Medicinal Cannabis

Leading the Next Evolution of Cannabis Healthcare


Building a clinically-justified business in rapid time


September 2018
Collaboration with US-based AXIM Biotechnologies to license products in Australia and New Zealand

December 2018
Licensed materials and intellectual property to support the production of generic Dronabinol (pure delta-9 Tetrahydrocannabinol (‘THC’)) capsules

January 2019
Relevant medicinal cannabis licenses received to import, export and distribute

March 2019
Partnered with Cannvalate; the largest network of medicinal cannabis prescribing doctors in Australia, representing over 30% of the total prescribing market

June 2019
Expected commencement of the first of four clinical trials in conjunction with Swinburne University and Cannvalate

Commercialisation Pathway – Unique products and established distribution



  • Medicinal Cannabis Oils
  • 4 products under clinical trials
  • Dronabinol for HIV and Cancer patients


  • Cannvalate MC Prescriber Network
  • Sales via internally generated Preferred Practitioner Network


  • One of the fastest growing sectors in the world


Strong potential for sales for medicinal cannabis products under the SAS within the 2019 Calendar year to open new revenue streams for Impression Healthcare



Immediate Gateway to procure sophisticated cannabinoid products


  • Exclusive license granted to Impression over CBD-based mouthwash and toothpaste targeting severe Gum Disease, known formally as Periodontitis or Periodontal Diseases.
  • Clinical trial to commence soon on a CBD mouthwash and toothpaste combined
  • Trial protocol being finalised and ethics submission occurring soon
  • Product supply agreement in place for commercial sales post clinical trials
  • First right of refusal over all current and future AXIM products for 3 years, until May 2022
  • AXIM has an extensive patent portfolio
  • First agreement now completed as a template for other product license opportunities
  • AXIM has also completed extensive work in IBS/IBD, Psoriasis/Atopic Dermatitis, Multiple Sclerosis, Opioid Addiction, Restless Leg Syndrome, Drug-related psychosis, Glaucoma, Parkinson’s Disease and Dementia

Distribution Agreement with the Largest Distributor of Medicinal Cannabis in Australia


Channel to market secured

  • Agreement with Cannvalate to distribute medicinal cannabis products in Australia with circa. 35-40% of all prescriptions and expanding in key global markets
  • Cannvalate has a network of more than 1000 prescribing doctors and 600 dispensing pharmacies
  • Facilitates sales for all current major sellers in the market including Althea Group, Bod Australia and Cann Group
  • Four products with specific indications under development and a medicinal cannabis oil for a range of indications being negotiated

Trials being conducted in partnership with industry key opinion leaders

  • Randomised Controlled Trials each of up to 40 participants conducted to demonstrate safety and efficacy to substantiate sales under the Special Access Schemes
  • The trials to be conducted in conjunction with Swinburne University of Technology and Cannvalate and represent in excess of $3M worth of expenditure with Impression’s cash contribution limited to $80,000 (plus GST) per trial
  • Impression retains all intellectual property associated with the trials
  • Progressive updates for all trials to be made to the ASX at key junctures

For the creation of 4 distinct products with clinical evidence

  • CBD Mouthwash and Toothpaste combined for reducing severe Gum Disease (Periodontitis) – commencing Q2 2019
  • A proprietary Dronabinol variant for Obstructive Sleep Apnoea Syndrome – commencing Q3 2019
  • Synthetic CBD Oil for improvement of Neuro-cognitive function following Concussion (Traumatic Brain Injury) – commencing Q3 2019
  • CBD Oil for TMJ Dysfunction (Temporomandibular Joint Dysfunction) – commencing Q3 2019

Soft Gel Capsule Manufacturing Alternative for Impression


  • The licencing arrangement with Resolution Chemicals (ResoChem) is intended to expedite the achievement of marketing authorisations of 2.5mg; 5.0mg and 10.0mg generic Dronabinol capsules for the USA, Canada, Australia and New Zealand
  • Dronabinol is traditionally used to treat:
    • loss of appetite in people with HIV/AIDS,
    • nausea and vomiting caused by chemotherapy, and
    • other potential treatment uses for Dronabinol include pain management and sleep apnoea
  • ResoChem has granted Impression the rights to all Intellectual Property (‘IP’) associated with the production of a complete non-synthetic Dronabinol product to assist with commercialisation in the exclusive countries
  • Manufacturing alternatives being considered and potential for other products to be manufactured using the machines and workspaces currently being evaluated
Impression Healthcare logo

Want The Latest From IHL?

Join our investor mailing list to be notified of announcements when they are made and sent all the latest investor materials as they are published. 

Thanks for signing up! We'll be in touch shortly.